COMMUNIQUÉS West-GlobeNewswire

Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer
04/03/2026
Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer Competitive funding award highlights Theolytics’ innovative [...]
Philips unveils Rembra CT at ECR 2026, setting a new benchmark for speed and patient access designed to support diagnostic confidence for acute and high-demand imaging environments
04/03/2026
March 4, 2026 CE Marked and 510(k) pending, Rembra’s advanced image reconstruction technology delivers up to 106 images per second [1] and a high throughput of up to 270 patients per day [2] to support faster diagnosis [...]
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
04/03/2026
REYKJAVIK, ICELAND (March 4, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
Independent study presented at ECR highlights REGENERA™ bioresorbable scaffold potential for breast restoration after lumpectomy
04/03/2026
Independent investigators from the University of Pisa presented new data at the 2026 European Congress of Radiology (ECR) Ultrasound follow-up documented predictable scaffold bioresorption and progressive soft-tissue [...]
Réaction aux attaques visant Carbios et ses dirigeants
04/03/2026
Clermont-Ferrand (France), 4 mars 2026 (08h45 CET). Carbios (Euronext Growth Paris : ALCRB) dénonce la campagne de déstabilisation dont elle fait l’objet depuis plusieurs mois et conteste formellement l’ensemble des [...]
Response to attacks against Carbios and its executives
04/03/2026
Clermont-Ferrand (France), March 4, 2026 (8:45 a.m. CET). Carbios (Euronext Growth Paris : ALCRB) denounces the destabilization operation to which it has been subjected for several months and formally contests all [...]
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
04/03/2026
Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ® Phase 3 trial of daridorexant [...]
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
04/03/2026
REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients [...]
BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy
04/03/2026
BASEL, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) -- BV100 Phase 1, single- and multiple-ascending dose clinical trial data include pharmacokinetics, safety and tolerability data. BV100 demonstrated a dose- [...]
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
04/03/2026
— Second clinical candidate from HUTCHMED’s next-generation ATTC platform — — Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March [...]
Male Power XL "Black Elixir" Claims Evaluated: 2026 Report Examines Ingredient Research, Proprietary Blend Transparency, and What Men Should Verify Before Buying
04/03/2026
A 2026 informational consumer report evaluating Male Power XL's "black elixir" marketing language, ingredient research context, proprietary blend limitations, pricing and policy terms shown on the official site, and [...]
AudiLeaf Ear Health Claims Evaluated: 2026 Report Examines Ingredients, Proprietary Blend Dosing, and What Consumers Should Verify Before Buying
04/03/2026
A 2026 informational consumer evaluation of AudiLeaf's ear health marketing claims, proprietary herbal blend ingredient research context, pricing structure, and what to verify before purchasing Aurora, CO, March 03, [...]
MemoTril Cognitive Support Claims Evaluated: Latest 2026 Consumer Report Examines MemoTril Brain Supplement Ingredients, Memory Enhancement Marketing, and What Consumers Should Verify
04/03/2026
Informational 2026 consumer report examining MemoTril brain supplement ingredients, cognitive support marketing claims, ingredient research context, pricing disclosures, and what consumers should verify before [...]
DermaFix Nail Fungus Treatment Gel Claims Evaluated in 2026 Market Report Covering Tea Tree Oil Research, Penetration Technology Positioning, and Pricing Transparency
04/03/2026
An informational industry analysis examining ingredient-level research, marketing positioning trends, regulatory context, and publicly listed pricing structures in the topical nail fungus category Sheridan, WY, March 03 [...]
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
03/03/2026
FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand [...]
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
03/03/2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its [...]
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting
03/03/2026
CHATHAM, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced today that a poster on [...]
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
03/03/2026
DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
03/03/2026
Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1A Duvakitug is currently in phase 3 clinical studies for ulcerative colitis (UC) and Crohn [...]

Pages